Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practic...

Descripción completa

Detalles Bibliográficos
Autores: Mas, Sergi, Juliá, Laura, Cuesta, Manuel J., Crespo Facorro, Benedicto|||0000-0001-9709-1276, Vázquez Bourgon, Javier|||0000-0002-5478-3376, Spuch, Carlos, González-Pinto, Ana, Ibáñez, Ángela, Usall, Judith, Romero-López-Alberca, Cristina, Catalán, Ana, Mané. Anna, Bernardo, Miquel
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/36631
Acceso en línea:https://hdl.handle.net/10902/36631
Access Level:acceso abierto
Palabra clave:Personalized medicine
Antipsychotic
Prediction
Psychosis
Pharmacogenetics
id ES_a45b5bb528bf5f6b22f35a9baaabb69a
oai_identifier_str oai:repositorio.unican.es:10902/36631
network_acronym_str ES
network_name_str España
repository_id_str
spelling Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocolMas, SergiJuliá, LauraCuesta, Manuel J.Crespo Facorro, Benedicto|||0000-0001-9709-1276Vázquez Bourgon, Javier|||0000-0002-5478-3376Spuch, CarlosGonzález-Pinto, AnaIbáñez, ÁngelaUsall, JudithRomero-López-Alberca, CristinaCatalán, AnaMané. AnnaBernardo, MiquelPersonalized medicineAntipsychoticPredictionPsychosisPharmacogeneticsThe application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the "Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes" study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from "Clinical Program on Early Phases of Psychosis" (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.Frontiers MediaUniversidad de Cantabria20242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/36631Frontiers in Psychiatry, 2025, 15, 1497565reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/366312026-06-02T12:39:31Z
dc.title.none.fl_str_mv Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
spellingShingle Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
Mas, Sergi
Personalized medicine
Antipsychotic
Prediction
Psychosis
Pharmacogenetics
title_short Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_full Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_fullStr Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_full_unstemmed Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
title_sort Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
dc.creator.none.fl_str_mv Mas, Sergi
Juliá, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto|||0000-0001-9709-1276
Vázquez Bourgon, Javier|||0000-0002-5478-3376
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalán, Ana
Mané. Anna
Bernardo, Miquel
author Mas, Sergi
author_facet Mas, Sergi
Juliá, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto|||0000-0001-9709-1276
Vázquez Bourgon, Javier|||0000-0002-5478-3376
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalán, Ana
Mané. Anna
Bernardo, Miquel
author_role author
author2 Juliá, Laura
Cuesta, Manuel J.
Crespo Facorro, Benedicto|||0000-0001-9709-1276
Vázquez Bourgon, Javier|||0000-0002-5478-3376
Spuch, Carlos
González-Pinto, Ana
Ibáñez, Ángela
Usall, Judith
Romero-López-Alberca, Cristina
Catalán, Ana
Mané. Anna
Bernardo, Miquel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Personalized medicine
Antipsychotic
Prediction
Psychosis
Pharmacogenetics
topic Personalized medicine
Antipsychotic
Prediction
Psychosis
Pharmacogenetics
description The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the "Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes" study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from "Clinical Program on Early Phases of Psychosis" (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/36631
url https://hdl.handle.net/10902/36631
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv Frontiers in Psychiatry, 2025, 15, 1497565
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415490464514048
score 15,811543

Similares en LA Referencia